MaltSci 麦伴科研

Appearance

Popular Reports / Cancer Research

This report is written by MaltSci based on the latest literature and research findings

What is the role of cancer metabolism in tumor growth? ​

Abstract ​

Cancer is a complex disease marked by uncontrolled cell growth, with recent research emphasizing the importance of metabolism in tumor progression. Cancer cells exhibit distinct metabolic alterations, such as the Warburg effect, where they preferentially utilize glycolysis for energy production even in the presence of oxygen. This metabolic reprogramming not only meets the energetic demands of rapidly dividing cells but also provides essential biosynthetic precursors for macromolecule synthesis. The tumor microenvironment, composed of various cell types, plays a significant role in shaping cancer metabolism, influencing nutrient availability and immune interactions. Understanding these metabolic pathways is crucial for developing effective therapeutic strategies. Recent studies indicate that targeting metabolic vulnerabilities can enhance therapeutic efficacy, with various metabolic inhibitors currently under investigation. However, challenges remain in fully elucidating the complexities of cancer metabolism, particularly due to the heterogeneity across different tumor types and the dynamic nature of metabolic adaptations within the tumor microenvironment. Future research should focus on tailoring therapeutic approaches to effectively target the metabolic dependencies of cancer cells while considering the context of their surrounding environment. This review aims to provide a comprehensive overview of cancer metabolism's role in tumor growth, exploring key metabolic pathways, interactions with the tumor microenvironment, and therapeutic implications.

Outline ​

This report will discuss the following questions.

  • 1 Introduction
  • 2 Overview of Cancer Metabolism
    • 2.1 The Warburg Effect
    • 2.2 Key Metabolic Pathways in Cancer
  • 3 Tumor Microenvironment and Metabolism
    • 3.1 Nutrient Availability and Utilization
    • 3.2 Interaction with Immune Cells
  • 4 Metabolic Reprogramming in Tumor Cells
    • 4.1 Alterations in Glycolysis and Oxidative Phosphorylation
    • 4.2 Role of Oncogenes and Tumor Suppressors
  • 5 Therapeutic Implications of Targeting Cancer Metabolism
    • 5.1 Metabolic Inhibitors in Clinical Trials
    • 5.2 Combination Therapies and Future Directions
  • 6 Challenges and Future Perspectives
    • 6.1 Limitations of Current Research
    • 6.2 Emerging Metabolic Targets
  • 7 Conclusion

1 Introduction ​

Cancer is a complex and multifaceted disease characterized by uncontrolled cell growth and proliferation. Recent advances in cancer research have increasingly highlighted the pivotal role of metabolism in tumor growth and progression. Tumor cells exhibit distinct metabolic alterations compared to normal cells, allowing them to thrive in hostile microenvironments. The concept of cancer metabolism, rooted in the pioneering work of Otto Warburg, suggests that cancer cells preferentially utilize glycolysis for energy production, even in the presence of oxygen, a phenomenon known as the Warburg effect. This metabolic reprogramming not only supports the energetic demands of rapidly dividing tumor cells but also provides critical biosynthetic precursors necessary for macromolecule synthesis, thereby facilitating tumorigenesis [1][2].

Understanding the metabolic pathways that underpin cancer cell proliferation is of paramount importance for developing effective therapeutic strategies. The reprogrammed metabolism of cancer cells is influenced by a multitude of factors, including genetic mutations in oncogenes and tumor suppressor genes, as well as interactions with the tumor microenvironment (TME). The TME is composed of various cell types, including stromal cells, immune cells, and fibroblasts, all of which contribute to the metabolic landscape of tumors. For instance, cancer-associated fibroblasts (CAFs) have been shown to play a significant role in metabolic coupling with tumor cells, providing essential nutrients and energy substrates that fuel tumor growth [3][4]. Additionally, the interplay between tumor metabolism and immune cell functions has been recognized as a crucial factor in cancer progression and immune evasion [5][6].

The significance of cancer metabolism extends beyond mere energy production; it encompasses the broader implications for therapeutic interventions. Recent studies have demonstrated that targeting metabolic vulnerabilities in cancer cells can lead to improved therapeutic efficacy. Various metabolic inhibitors are currently under investigation in clinical trials, aiming to exploit the unique metabolic dependencies of tumor cells [7][8]. Furthermore, the development of combination therapies that integrate metabolic targeting with conventional treatments holds promise for enhancing patient outcomes [9].

Despite the growing body of knowledge, challenges remain in fully elucidating the complexities of cancer metabolism. The heterogeneity of metabolic pathways across different tumor types, as well as the dynamic nature of metabolic adaptations within the TME, necessitates further investigation [10][11]. Understanding these intricate relationships will be essential for developing tailored therapeutic approaches that effectively target the metabolic vulnerabilities of cancer cells while considering the context of the surrounding microenvironment.

This review is organized into several sections to provide a comprehensive overview of cancer metabolism and its role in tumor growth. Section 2 will delve into the overview of cancer metabolism, including the Warburg effect and key metabolic pathways involved in cancer. Section 3 will explore the interactions between the tumor microenvironment and cancer metabolism, focusing on nutrient availability and the role of immune cells. In Section 4, we will examine metabolic reprogramming in tumor cells, highlighting alterations in glycolysis and oxidative phosphorylation, as well as the contributions of oncogenes and tumor suppressors. Section 5 will discuss the therapeutic implications of targeting cancer metabolism, including ongoing clinical trials and future directions. Finally, Section 6 will address the challenges and future perspectives in the field of cancer metabolism, setting the stage for concluding remarks in Section 7. By elucidating the intricate relationship between cancer metabolism and tumor growth, this review aims to contribute to the ongoing discourse on innovative strategies for cancer treatment.

2 Overview of Cancer Metabolism ​

2.1 The Warburg Effect ​

Cancer metabolism plays a critical role in tumor growth, characterized primarily by the Warburg effect, which is a metabolic phenomenon first described by Otto Warburg in the 1920s. This effect highlights a fundamental alteration in the energy production pathways of cancer cells, distinguishing them from normal cells. Normal cells predominantly utilize mitochondrial oxidative phosphorylation to generate ATP, whereas cancer cells preferentially rely on glycolysis, converting glucose to lactate even in the presence of sufficient oxygen. This shift towards aerobic glycolysis is known as the Warburg effect and serves as a hallmark of cancer metabolism[12].

The Warburg effect facilitates rapid energy acquisition and biosynthesis necessary for tumor growth and proliferation. Cancer cells exhibit increased glucose uptake rates and elevated lactate production, which are crucial adaptations that enable them to meet heightened energy and biosynthetic demands associated with uncontrolled proliferation[13]. This metabolic reprogramming is not merely a byproduct of cancer but is actively driven by oncogenes and tumor suppressor genes that influence metabolic pathways. For instance, mutations in these genes can promote a metabolic phenotype that supports malignant behavior, thus underscoring the interplay between genetic alterations and metabolic changes in cancer cells[14].

Moreover, the tumor microenvironment significantly influences cancer metabolism. Factors such as nutrient availability, oxygen levels, and metabolic waste accumulation can alter the metabolic landscape of tumors. Cancer cells adapt their metabolism to survive and thrive in these varying microenvironments, often exhibiting a preference for glycolysis as a means to sustain growth under adverse conditions[15]. The communication within the tumor microenvironment also plays a pivotal role in regulating cancer cell metabolism, impacting tumor progression and therapeutic resistance[13].

Recent studies have emphasized the potential of targeting the Warburg effect and related metabolic pathways as therapeutic strategies. By disrupting the metabolic advantages conferred by glycolysis, novel treatments could enhance the efficacy of existing therapies and improve patient outcomes[16]. Furthermore, the understanding of cancer metabolism, particularly the Warburg effect, has paved the way for innovative diagnostic tools and therapeutic approaches aimed at manipulating tumor metabolism for clinical benefit[17].

In summary, cancer metabolism, especially through the Warburg effect, is integral to tumor growth and survival. The shift towards glycolysis not only supports the energy needs of rapidly proliferating cancer cells but also represents a critical target for therapeutic intervention, offering promising avenues for the development of effective cancer treatments.

2.2 Key Metabolic Pathways in Cancer ​

Cancer metabolism plays a crucial role in tumor growth, characterized by the unique ways in which cancer cells utilize nutrients and energy to support their proliferation. Unlike normal cells, cancer cells exhibit a distinct metabolic profile, marked by an increased reliance on glucose and glutamine as primary energy sources, and they undergo metabolic reprogramming to meet their heightened bioenergetic and biosynthetic demands.

One of the hallmark features of cancer metabolism is the Warburg effect, where cancer cells preferentially utilize aerobic glycolysis even in the presence of sufficient oxygen. This metabolic adaptation allows for rapid ATP production and the generation of metabolic intermediates necessary for biosynthesis, supporting continuous cell growth and division. In addition to glycolysis, cancer cells also exploit mitochondrial metabolism, which plays a critical role in sustaining energy production and supporting biosynthetic pathways through the tricarboxylic acid (TCA) cycle and oxidative phosphorylation (OXPHOS) [2].

The interplay between tumor cells and their microenvironment significantly influences cancer metabolism. Tumor-associated fibroblasts (CAFs), which are abundant in the tumor microenvironment, undergo metabolic reprogramming to support tumor growth. These CAFs can provide essential nutrients and metabolites, such as lactate, fatty acids, and amino acids, to cancer cells, facilitating their proliferation and survival. This metabolic coupling creates a nutrient-rich microenvironment that is conducive to tumor growth [3].

Moreover, the tumor microenvironment is characterized by hypoxia and nutrient deprivation, prompting cancer cells to adapt their metabolic pathways. This adaptability is facilitated by various oncogenes and tumor suppressor genes that rewire cellular metabolism, enhancing the ability of cancer cells to scavenge nutrients and survive in hostile conditions [7].

Key metabolic pathways involved in cancer growth include glycolysis, glutaminolysis, and fatty acid oxidation. Increased glycolytic activity not only supports energy production but also contributes to the production of lactate, which can further modulate the tumor microenvironment by promoting immune evasion and enhancing angiogenesis [6]. Glutamine metabolism is also vital, as it serves as a nitrogen source for nucleotide synthesis and replenishes TCA cycle intermediates, thereby supporting rapid cell proliferation [18].

Furthermore, cancer metabolism is closely linked to immune evasion. The metabolic alterations in tumor cells can create an immunosuppressive microenvironment, hindering the efficacy of anti-tumor immune responses. For instance, the accumulation of immunomodulatory metabolites, such as lactate and kynurenine, can impair T cell function and facilitate tumor progression [1].

In summary, cancer metabolism is integral to tumor growth, involving a complex network of metabolic pathways that support the energy and biosynthetic needs of rapidly proliferating cancer cells. The interaction between tumor cells and their microenvironment further enhances these metabolic adaptations, making cancer metabolism a critical area of research for developing targeted therapeutic strategies aimed at disrupting these metabolic processes and improving patient outcomes.

3 Tumor Microenvironment and Metabolism ​

3.1 Nutrient Availability and Utilization ​

Cancer metabolism plays a crucial role in tumor growth by enabling cancer cells to utilize nutrients and energy efficiently to support their rapid proliferation. This altered metabolism is characterized by a distinct metabolic profile that differs from that of normal cells, allowing tumor cells to thrive even in challenging environments. Key aspects of cancer metabolism include an increased reliance on specific nutrients such as glucose and glutamine, which serve as primary energy sources and building blocks for cellular growth.

The tumor microenvironment significantly influences nutrient availability and utilization, which is vital for cancer progression. Factors such as tissue of origin, local nutrient supply, and the interactions with stromal and immune cells shape the metabolic landscape within tumors. For instance, the microenvironment is often characterized by a chronic deficiency of oxygen and nutrients, compelling cancer cells to adapt their metabolic pathways to scavenge for alternative sources of energy. This adaptability is facilitated by processes such as autophagy and macropinocytosis, which allow cancer cells to exploit extracellular nutrients, including proteins and lipids, thus maintaining their anabolic demands and survival [8].

Recent studies have highlighted that the composition of the tumor interstitial fluid (TIF) closely resembles that of adjacent normal tissue interstitial fluid (KIF), indicating that tissue-specific factors play a dominant role in nutrient dynamics. This suggests that the nutrient availability in tumors may be more influenced by non-cancer-driven factors than by tumor-induced changes [19]. Furthermore, metabolic interactions between tumor cells and the surrounding stroma are essential for supporting tumor growth, as they form metabolic networks that facilitate nutrient exchange and utilization [7].

Moreover, cancer cells exhibit a high degree of metabolic flexibility, allowing them to adapt to varying nutrient levels within the tumor microenvironment. This flexibility is critical as it enables tumor cells to survive and proliferate despite fluctuations in nutrient supply [20]. The presence of various nutrients, including lipids and amino acids, not only fuels the bioenergetic and biosynthetic needs of cancer cells but also influences immune cell behavior within the tumor ecosystem, thereby affecting the overall tumor growth and immune evasion [21].

In conclusion, cancer metabolism is intricately linked to tumor growth through its dependence on nutrient availability and utilization. The tumor microenvironment, with its unique nutrient composition and interactions with stromal cells, plays a pivotal role in shaping the metabolic pathways that support cancer cell proliferation. Understanding these metabolic dynamics offers potential therapeutic targets for treating cancer by disrupting the nutrient supply and metabolic interactions that sustain tumor growth [22][23].

3.2 Interaction with Immune Cells ​

Cancer metabolism plays a pivotal role in tumor growth by altering the metabolic pathways of tumor cells and their interactions with the tumor microenvironment, particularly with immune cells. The tumor microenvironment is characterized by a complex interplay of various cellular components, including tumor cells, immune cells, and stromal cells, which collectively influence tumor progression and immune evasion.

The metabolic reprogramming of cancer cells is one of the hallmarks of malignancy. Tumor cells often undergo significant metabolic changes that enable them to thrive in a nutrient-poor and hypoxic environment. These alterations support rapid proliferation by providing the necessary energy and building blocks for biosynthesis. For instance, tumor cells can utilize glycolysis, even in the presence of oxygen (a phenomenon known as the Warburg effect), to generate ATP and metabolic intermediates that are crucial for cell growth and division [8].

Moreover, the tumor microenvironment is not merely a passive background; it actively participates in shaping the metabolic landscape. Tumor-associated immune cells, including myeloid cells and lymphocytes, can acquire a tumor-supportive, anti-inflammatory phenotype through their interactions with cancer cells. This phenotypic shift is influenced by microenvironmental factors such as inflammation and hypoxia, which contribute to creating a niche that favors tumor growth [24]. The availability of nutrients, particularly amino acids and lipids, is critical in this context. Amino acids not only serve as building blocks for protein synthesis but also play significant roles in modulating signaling pathways and maintaining redox homeostasis within tumor cells [25].

The interaction between tumor cells and immune cells is multifaceted and complex. For example, the metabolic reprogramming of tumor cells can influence the behavior of immune cells, thereby reshaping the anti-tumor immune response. Cancer cells can exploit immune cell metabolism to create a more favorable environment for their survival and proliferation. This can lead to immune evasion, where tumor cells escape detection and destruction by the immune system [26]. Furthermore, the acidic and nutrient-depleted conditions of the tumor microenvironment can promote metabolic competition, leading to a symbiotic relationship between cancer cells and stromal cells, which further facilitates tumor growth [23].

In summary, cancer metabolism is intricately linked to tumor growth through its influence on both tumor cells and the immune microenvironment. The metabolic adaptations of cancer cells not only support their survival and proliferation but also modulate the functional capabilities of immune cells, ultimately impacting the overall tumor progression and response to therapies. Understanding these interactions provides critical insights into potential therapeutic strategies aimed at disrupting the metabolic dependencies of cancer cells while enhancing anti-tumor immune responses [27][28].

4 Metabolic Reprogramming in Tumor Cells ​

4.1 Alterations in Glycolysis and Oxidative Phosphorylation ​

Cancer metabolism plays a pivotal role in tumor growth by enabling cancer cells to adapt to their microenvironment and meet the high energy and biosynthetic demands associated with rapid proliferation. One of the hallmark features of cancer cells is their ability to undergo metabolic reprogramming, particularly characterized by alterations in glycolysis and oxidative phosphorylation.

Glycolysis, the process by which glucose is converted into pyruvate, is significantly upregulated in cancer cells, a phenomenon often referred to as the Warburg effect. This metabolic shift allows cancer cells to generate ATP rapidly even in the presence of oxygen, leading to increased lactate production. The enhanced glycolytic pathway supports not only energy production but also provides intermediates for biosynthetic pathways necessary for cell growth and division. For instance, glucose-derived carbons are utilized in the synthesis of fatty acids and nucleotides, essential components for the rapid proliferation of tumor cells [29].

In addition to glycolysis, oxidative phosphorylation (OXPHOS) also plays a crucial role in cancer metabolism. Although traditionally viewed as less dominant in cancer cells, recent studies indicate that OXPHOS can be a primary ATP source for many tumors, particularly under certain microenvironmental conditions. The balance between glycolysis and OXPHOS is tightly regulated and can shift depending on nutrient availability and cellular stressors [30]. This metabolic flexibility allows cancer cells to survive in low-oxygen environments typical of solid tumors, where nutrient availability is often compromised [31].

The interplay between glycolysis and OXPHOS is essential for maintaining metabolic plasticity, which is crucial for tumor initiation and progression. Cancer cells often exhibit a dual capacity for utilizing both metabolic pathways, allowing them to adapt to varying conditions and maintain growth even under metabolic stress [32]. For example, studies have shown that mitochondrial respiration can be upregulated in response to changes in nutrient supply, enabling cancer cells to sustain their bioenergetic needs and support invasive behaviors [33].

Furthermore, metabolic reprogramming is influenced by various factors, including oncogenes, tumor suppressors, and the tumor microenvironment. These factors can induce the expression of key enzymes and transporters involved in glycolysis and OXPHOS, enhancing the metabolic capabilities of cancer cells [10]. For instance, the tumor suppressor p53 has been shown to regulate aerobic glycolysis and oxidative phosphorylation, thus playing a significant role in tumor metabolism and offering potential therapeutic targets [34].

In summary, cancer metabolism, through alterations in glycolysis and oxidative phosphorylation, facilitates tumor growth by providing the necessary energy and building blocks for rapid cell division. The metabolic reprogramming observed in cancer cells not only supports their proliferation but also contributes to their survival in challenging microenvironments, highlighting the importance of understanding these metabolic pathways for developing effective cancer therapies. Continued research into the complexities of cancer metabolism is crucial for identifying novel therapeutic strategies that can disrupt these adaptive mechanisms and improve treatment outcomes.

4.2 Role of Oncogenes and Tumor Suppressors ​

Cancer metabolism plays a crucial role in tumor growth, primarily through the process of metabolic reprogramming that tumor cells undergo to meet their increased bioenergetic and biosynthetic demands. This metabolic reprogramming is characterized by a shift in energy production pathways and nutrient utilization, allowing cancer cells to sustain rapid proliferation and survival in adverse conditions.

One of the hallmark features of cancer metabolism is the reliance on aerobic glycolysis, also known as the Warburg effect, where cancer cells preferentially convert glucose to lactate even in the presence of oxygen. This shift not only supports ATP production but also provides intermediates necessary for the synthesis of nucleotides, amino acids, and lipids, which are essential for cell growth and division. Increased consumption of glutamine is another significant aspect of cancer metabolism, as it serves as a vital carbon source and is involved in various biosynthetic pathways [8].

Oncogenes and tumor suppressor genes play pivotal roles in orchestrating these metabolic changes. Mutations in oncogenes, such as KRAS and MYC, can activate metabolic pathways that promote tumorigenesis. For instance, oncogenic mutations can enhance glucose uptake and glycolytic activity, leading to increased lactate production and altered redox states within the tumor microenvironment [35]. Conversely, tumor suppressors like p53 have been shown to regulate metabolic pathways by promoting oxidative phosphorylation and inhibiting glycolysis, thereby counteracting the metabolic adaptations that favor tumor growth [34].

Moreover, the interactions between cancer cells and the tumor microenvironment further complicate the metabolic landscape. Tumor-associated fibroblasts and immune cells can provide essential nutrients and metabolic support to cancer cells, creating a dynamic and reciprocal metabolic interplay that sustains tumor growth [36]. For example, carcinoma-associated fibroblasts can release lactate and other metabolites that cancer cells utilize for energy and growth, effectively "feeding" the tumor [18].

The metabolic reprogramming in cancer cells is not merely a consequence of uncontrolled proliferation; it can also actively drive tumorigenesis. Evidence suggests that metabolic alterations can influence genetic and epigenetic changes within cancer cells, thereby facilitating further oncogenic processes [37]. This complex interplay between metabolism, oncogenes, and tumor suppressors underscores the potential for targeting metabolic pathways as a therapeutic strategy in cancer treatment [7].

In summary, cancer metabolism is integral to tumor growth through its reprogramming mechanisms that enhance the availability of energy and biosynthetic precursors. Oncogenes and tumor suppressors are critical regulators of these metabolic pathways, and their interactions with the tumor microenvironment further support the viability and proliferation of cancer cells. Understanding these metabolic dynamics presents opportunities for developing novel therapeutic interventions aimed at disrupting the metabolic dependencies of tumors.

5 Therapeutic Implications of Targeting Cancer Metabolism ​

5.1 Metabolic Inhibitors in Clinical Trials ​

Cancer metabolism plays a pivotal role in tumor growth, influencing not only the energy supply but also the biosynthetic processes necessary for rapid cell proliferation. The altered metabolic profile of cancer cells is characterized by increased reliance on glucose and glutamine, alongside enhanced glycolysis and lactate production, which provide the energy and building blocks required for tumor growth and survival [7]. This metabolic reprogramming is essential for accommodating the high energetic demands of tumor cells, facilitating processes such as increased proliferation and metastasis [38].

The therapeutic implications of targeting cancer metabolism are significant. By understanding the metabolic vulnerabilities of cancer cells, researchers are exploring various strategies to inhibit key metabolic pathways. For instance, targeting glycolysis, the Warburg effect, and mitochondrial metabolism has emerged as a promising approach to impede tumor growth [2]. These strategies aim to exploit the unique metabolic dependencies of cancer cells, which differ markedly from those of normal cells, to selectively induce tumor cell death while sparing healthy tissues [39].

Clinical trials are increasingly evaluating metabolic inhibitors as potential therapeutic agents in cancer treatment. For example, recent studies have highlighted the efficacy of inhibitors targeting mitochondrial metabolism, which plays a crucial role in supporting tumor growth by providing essential metabolites for macromolecule synthesis [40]. Furthermore, the modulation of metabolic pathways such as those involving citrate has been proposed as a novel strategy to enhance immune responses against tumors, thereby improving the efficacy of immunotherapy [41].

In summary, cancer metabolism is intricately linked to tumor growth and presents a viable target for therapeutic intervention. The ongoing exploration of metabolic inhibitors in clinical trials underscores the potential of this approach to improve patient outcomes by specifically targeting the metabolic adaptations that characterize cancer cells [42]. As research continues to unveil the complexities of cancer metabolism, it is anticipated that these insights will lead to the development of innovative treatment strategies that leverage metabolic vulnerabilities for enhanced therapeutic efficacy.

5.2 Combination Therapies and Future Directions ​

Cancer metabolism plays a crucial role in tumor growth by providing the necessary energy and building blocks required for rapid cell proliferation. Tumor cells exhibit distinct metabolic profiles compared to normal cells, characterized by increased reliance on glucose and glutamine, elevated glycolysis, and altered utilization of metabolic intermediates such as ATP, NADH, and NADPH. These metabolic adaptations support the high bioenergetic and biosynthetic demands of tumor growth, enabling cancer cells to thrive even in adverse microenvironments [7].

The tumor microenvironment significantly influences cancer metabolism, as cancer and stromal cells interact and modulate each other's metabolic pathways. This crosstalk is essential for tumor progression and immune evasion, as metabolic reprogramming can lead to an immunosuppressive environment that facilitates tumor growth [43]. Additionally, the metabolic plasticity of tumors poses challenges for therapeutic interventions, as cancer cells can adapt their metabolic strategies in response to treatment [8].

Targeting cancer metabolism presents a promising therapeutic strategy, with various approaches under investigation. For instance, inhibiting key metabolic pathways such as glycolysis and mitochondrial function has shown potential in suppressing tumor growth. Recent studies emphasize the importance of understanding the metabolic vulnerabilities of different cancer types to design effective combination therapies [2].

Combination therapies that integrate metabolic targeting with traditional modalities, such as chemotherapy and immunotherapy, may enhance treatment efficacy. By exploiting the unique metabolic characteristics of tumors, these strategies aim to overcome resistance mechanisms and improve patient outcomes. Furthermore, ongoing research into the role of epigenetic regulation in tumor metabolism is expected to yield novel therapeutic targets, paving the way for personalized cancer treatment approaches [39].

In conclusion, the interplay between cancer metabolism and tumor growth is complex and multifaceted, with significant implications for therapeutic development. Future directions in this field will likely focus on elucidating the specific metabolic pathways involved in different cancer types, optimizing combination therapies, and leveraging the tumor microenvironment to enhance treatment efficacy [40]. Understanding these dynamics will be essential for the advancement of precision medicine in oncology.

6 Challenges and Future Perspectives ​

6.1 Limitations of Current Research ​

Cancer metabolism plays a crucial role in tumor growth by enabling cancer cells to adapt their metabolic processes to meet the increased demands for energy and biosynthetic precursors necessary for rapid proliferation. Cancer cells exhibit a unique metabolic profile characterized by an enhanced reliance on glucose and glutamine, alongside altered utilization of key metabolic intermediates such as ATP, NADH, and NADPH. This metabolic reprogramming is essential for supporting the growth and division of tumor cells, which differ significantly from normal cells in their nutrient metabolism [7].

The metabolic alterations observed in cancer cells are driven by various factors, including mutations in oncogenes and tumor suppressor genes, as well as the tumor microenvironment. These changes facilitate the provision of energy and building blocks necessary for tumor growth. Notably, the interplay between tumor metabolism and lipid metabolism within the tumor microenvironment is significant, with reactive oxygen species (ROS) also playing a role as potential anti-tumor agents by mediating various signaling pathways [7].

Moreover, the Warburg effect, which describes the tendency of cancer cells to favor aerobic glycolysis even in the presence of oxygen, is a critical aspect of cancer metabolism. This phenomenon allows for rapid energy production and the generation of metabolic intermediates that are crucial for the biosynthesis of macromolecules [2]. In parallel, mitochondrial metabolism supports tumor viability by orchestrating the tricarboxylic acid (TCA) cycle and electron transport chain, which provide a reliable source of biosynthetic precursors [2].

Despite the advancements in understanding cancer metabolism, several challenges and limitations remain in current research. One major challenge is the metabolic plasticity of tumors, which enables them to adapt to various environmental stresses and therapeutic interventions. This plasticity complicates the targeting of metabolic pathways for therapeutic purposes, as tumors can often switch to alternative pathways to sustain their growth [8]. Furthermore, the role of the tumor microenvironment, including stromal and immune cells, in influencing tumor metabolism is complex and not fully understood. The metabolic interactions between tumor cells and their microenvironment can create an immunosuppressive context that further promotes tumor progression and immune evasion [5].

Future research perspectives should focus on elucidating the intricate metabolic networks within tumors and their interactions with the surrounding microenvironment. Advanced technologies that allow for the investigation of metabolism at the unicellular level, without altering tumor tissue, are essential for gaining deeper insights into the dynamic nature of cancer metabolism [7]. Additionally, exploring the therapeutic potential of targeting metabolic pathways, both in tumor cells and their microenvironment, could yield novel strategies for cancer treatment. As our understanding of cancer metabolism evolves, it may lead to innovative therapeutic approaches that can effectively combat tumor growth and improve patient outcomes [10].

6.2 Emerging Metabolic Targets ​

Cancer metabolism plays a critical role in tumor growth, characterized by distinct metabolic alterations that enable cancer cells to meet their increased energy and biosynthetic demands. Tumor cells often exhibit a unique metabolic profile that diverges significantly from that of normal cells, primarily marked by heightened reliance on glucose and glutamine as energy sources. This metabolic reprogramming is not merely a consequence of increased cell proliferation but is also intricately linked to the tumor microenvironment, which includes interactions with stromal cells, immune cells, and the extracellular matrix[7][8].

The metabolic adaptations in cancer cells facilitate their growth and survival under conditions that would typically induce cell death. These adaptations include enhanced glycolysis, even in the presence of oxygen (the Warburg effect), increased fatty acid synthesis, and alterations in nucleotide metabolism[2][44]. Such changes support rapid proliferation and contribute to the development of therapeutic resistance[45].

Despite the potential for targeting cancer metabolism therapeutically, several challenges remain. The metabolic plasticity of tumors complicates treatment strategies, as cancer cells can adapt to metabolic interventions by utilizing alternative pathways or nutrients. For instance, cancer cells can engage in autophagy and macropinocytosis to scavenge nutrients from their environment, which poses a significant hurdle in developing effective metabolic-targeted therapies[7][8].

Future perspectives in cancer metabolism research focus on identifying specific metabolic vulnerabilities that can be exploited for therapeutic gain. This includes understanding the dynamic interactions between cancer cells and their microenvironment, which contribute to metabolic reprogramming. For example, recent studies emphasize the role of the tumor microbiome and its metabolites in modulating tumor metabolism and immune responses, presenting novel avenues for intervention[46].

Emerging metabolic targets include pathways involved in glucose, lipid, and nucleotide metabolism, as well as the signaling mechanisms that underpin these metabolic changes. Therapeutic strategies are being developed to disrupt these pathways, with a focus on combination therapies that integrate metabolic targeting with immunotherapy to enhance treatment efficacy[45][47].

Overall, the exploration of cancer metabolism continues to unveil new insights into tumor biology and therapeutic strategies, with the goal of improving patient outcomes through precision targeting of metabolic pathways. The integration of advanced technologies for metabolic profiling and the development of novel drug delivery systems are expected to play pivotal roles in overcoming current challenges and advancing the field of cancer therapy[7][45].

7 Conclusion ​

This review highlights the critical role of cancer metabolism in tumor growth, emphasizing the unique metabolic adaptations that cancer cells undergo to meet their increased energy and biosynthetic demands. The Warburg effect, characterized by the preferential use of glycolysis even in the presence of oxygen, serves as a hallmark of cancer metabolism, enabling rapid ATP production and supporting the synthesis of macromolecules necessary for tumor proliferation. The interaction between tumor cells and the tumor microenvironment is also crucial, as it influences nutrient availability and immune responses, creating a favorable niche for cancer progression. Despite the advancements in understanding cancer metabolism, challenges such as metabolic plasticity and the complex interplay with the tumor microenvironment remain. Future research should focus on elucidating these intricate metabolic networks and exploring novel therapeutic strategies that target metabolic vulnerabilities in cancer cells while considering the surrounding microenvironment. This approach could lead to innovative treatments that effectively disrupt the metabolic processes sustaining tumor growth and enhance patient outcomes.

References ​

  • [1] Chi Van Dang;Jung-Whan Kim. Convergence of Cancer Metabolism and Immunity: an Overview.. Biomolecules & therapeutics(IF=3.2). 2018. PMID:29212301. DOI: 10.4062/biomolther.2017.194.
  • [2] Yongxin Yu;Yulang Jiang;Christian Glandorff;Mingyu Sun. Exploring the mystery of tumor metabolism: Warburg effect and mitochondrial metabolism fighting side by side.. Cellular signalling(IF=3.7). 2024. PMID:38815642. DOI: 10.1016/j.cellsig.2024.111239.
  • [3] Ubaldo E Martinez-Outschoorn;Michael P Lisanti;Federica Sotgia. Catabolic cancer-associated fibroblasts transfer energy and biomass to anabolic cancer cells, fueling tumor growth.. Seminars in cancer biology(IF=15.7). 2014. PMID:24486645. DOI: .
  • [4] Ruyue Li;Yintao Li. Role of metabolic reprogramming of cancer‑associated fibroblasts in tumor development and progression (Review).. International journal of oncology(IF=4.9). 2025. PMID:40878935. DOI: .
  • [5] Thomas Boyer;Céline Blaye;Nicolas Larmonier;Charlotte Domblides. Influence of the Metabolism on Myeloid Cell Functions in Cancers: Clinical Perspectives.. Cells(IF=5.2). 2022. PMID:35159363. DOI: 10.3390/cells11030554.
  • [6] Haidong Tang;Yang-Xin Fu. Immune Evasion in Tumor's Own Sweet Way.. Cell metabolism(IF=30.9). 2018. PMID:29628418. DOI: 10.1016/j.cmet.2018.03.013.
  • [7] Tobias Achu Muluh;Xing-Sheng Shu;Ying Ying. Targeting cancer metabolic vulnerabilities for advanced therapeutic efficacy.. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie(IF=7.5). 2023. PMID:37031495. DOI: 10.1016/j.biopha.2023.114658.
  • [8] Alec C Kimmelman;Mara H Sherman. The Role of Stroma in Cancer Metabolism.. Cold Spring Harbor perspectives in medicine(IF=10.1). 2024. PMID:37696660. DOI: 10.1101/cshperspect.a041540.
  • [9] Inmaculada Martínez-Reyes;Navdeep S Chandel. Cancer metabolism: looking forward.. Nature reviews. Cancer(IF=66.8). 2021. PMID:34272515. DOI: 10.1038/s41568-021-00378-6.
  • [10] Jesse Bucksot;Katherine Ritchie;Matthew Biancalana;John A Cole;Daniel Cook. Pan-Cancer, Genome-Scale Metabolic Network Analysis of over 10,000 Patients Elucidates Relationship between Metabolism and Survival.. Cancers(IF=4.4). 2024. PMID:39001365. DOI: 10.3390/cancers16132302.
  • [11] Ruolei Wang;Lirong Liang;Misaki Matsumoto;Kazumi Iwata;Atsushi Umemura;Feng He. Reactive Oxygen Species and NRF2 Signaling, Friends or Foes in Cancer?. Biomolecules(IF=4.8). 2023. PMID:36830722. DOI: 10.3390/biom13020353.
  • [12] Ralph J DeBerardinis. Is cancer a disease of abnormal cellular metabolism? New angles on an old idea.. Genetics in medicine : official journal of the American College of Medical Genetics(IF=6.2). 2008. PMID:18941420. DOI: 10.1097/GIM.0b013e31818b0d9b.
  • [13] Zeinab Kooshan;Lilibeth Cárdenas-Piedra;Judith Clements;Jyotsna Batra. Glycolysis, the sweet appetite of the tumor microenvironment.. Cancer letters(IF=10.1). 2024. PMID:39127341. DOI: 10.1016/j.canlet.2024.217156.
  • [14] Yuhua Zhao;Hao Liu;Adam I Riker;Oystein Fodstad;Susan P Ledoux;Glenn L Wilson;Ming Tan. Emerging metabolic targets in cancer therapy.. Frontiers in bioscience (Landmark edition)(IF=3.1). 2011. PMID:21196269. DOI: 10.2741/3826.
  • [15] Mingzhe Xu;Junjie Fei;Zhi-Xiong Xiao;Yong Yi. Energy stress and adaptation strategy of tumor cells in different microenvironments: from primary tumors to distant metastases.. Acta biochimica et biophysica Sinica(IF=3.4). 2025. PMID:40620074. DOI: 10.3724/abbs.2025106.
  • [16] Minru Liao;Dahong Yao;Lifeng Wu;Chaodan Luo;Zhiwen Wang;Jin Zhang;Bo Liu. Targeting the Warburg effect: A revisited perspective from molecular mechanisms to traditional and innovative therapeutic strategies in cancer.. Acta pharmaceutica Sinica. B(IF=14.6). 2024. PMID:38487001. DOI: 10.1016/j.apsb.2023.12.003.
  • [17] U G A Sattler;F Hirschhaeuser;W F Mueller-Klieser. Manipulation of glycolysis in malignant tumors: fantasy or therapy?. Current medicinal chemistry(IF=3.5). 2010. PMID:19941476. DOI: 10.2174/092986710790112657.
  • [18] Hilary A Coller. Is cancer a metabolic disease?. The American journal of pathology(IF=3.6). 2014. PMID:24139946. DOI: .
  • [19] Keene L Abbott;Ahmed Ali;Bradley I Reinfeld;Amy Deik;Sonu Subudhi;Madelyn D Landis;Rachel A Hongo;Kirsten L Young;Tenzin Kunchok;Christopher S Nabel;Kayla D Crowder;Johnathan R Kent;Maria Lucia L Madariaga;Rakesh K Jain;Kathryn E Beckermann;Caroline A Lewis;Clary B Clish;Alexander Muir;W Kimryn Rathmell;Jeffrey Rathmell;Matthew G Vander Heiden. Metabolite profiling of human renal cell carcinoma reveals tissue-origin dominance in nutrient availability.. eLife(IF=6.4). 2024. PMID:38787918. DOI: .
  • [20] Gabriele Grasmann;Ayusi Mondal;Katharina Leithner. Flexibility and Adaptation of Cancer Cells in a Heterogenous Metabolic Microenvironment.. International journal of molecular sciences(IF=4.9). 2021. PMID:33540663. DOI: 10.3390/ijms22031476.
  • [21] Jannis Wißfeld;Anke Werner;Xin Yan;Nora Ten Bosch;Guoliang Cui. Metabolic regulation of immune responses to cancer.. Cancer biology & medicine(IF=8.4). 2022. PMID:36269001. DOI: .
  • [22] Graham P Lobel;Yanqing Jiang;M Celeste Simon. Tumor microenvironmental nutrients, cellular responses, and cancer.. Cell chemical biology(IF=7.2). 2023. PMID:37703882. DOI: 10.1016/j.chembiol.2023.08.011.
  • [23] Haoqiang Yang;Jinghui Li;Yiting Niu;Tao Zhou;Pengyu Zhang;Yang Liu;Yanjun Li. Interactions between the metabolic reprogramming of liver cancer and tumor microenvironment.. Frontiers in immunology(IF=5.9). 2025. PMID:40028341. DOI: 10.3389/fimmu.2025.1494788.
  • [24] Javier Mora;Christina Mertens;Julia K Meier;Dominik C Fuhrmann;Bernhard Brüne;Michaela Jung. Strategies to Interfere with Tumor Metabolism through the Interplay of Innate and Adaptive Immunity.. Cells(IF=5.2). 2019. PMID:31083487. DOI: 10.3390/cells8050445.
  • [25] Xiaohong Liu;Bo Ren;Jie Ren;Minzhi Gu;Lei You;Yupei Zhao. The significant role of amino acid metabolic reprogramming in cancer.. Cell communication and signaling : CCS(IF=8.9). 2024. PMID:39069612. DOI: 10.1186/s12964-024-01760-1.
  • [26] Jinpeng Chen;Sheng Wang;Yue Ding;Duo Xu;Shiya Zheng. Radiotherapy-induced alterations in tumor microenvironment: metabolism and immunity.. Frontiers in cell and developmental biology(IF=4.3). 2025. PMID:40356601. DOI: 10.3389/fcell.2025.1568634.
  • [27] Yingming Zhou;Hu Wang;Yi Luo;Biguang Tuo;Xuemei Liu;Taolang Li. Effect of metabolism on the immune microenvironment of breast cancer.. Biochimica et biophysica acta. Reviews on cancer(IF=8.3). 2023. PMID:36813054. DOI: 10.1016/j.bbcan.2023.188861.
  • [28] Yanru Long;Houhui Shi;Yuedong He;Xiaorong Qi. Analyzing the impact of metabolism on immune cells in tumor microenvironment to promote the development of immunotherapy.. Frontiers in immunology(IF=5.9). 2023. PMID:38264667. DOI: 10.3389/fimmu.2023.1307228.
  • [29] Susana Romero-Garcia;Jose Sullivan Lopez-Gonzalez;José Luis Báez-Viveros;Dolores Aguilar-Cazares;Heriberto Prado-Garcia. Tumor cell metabolism: an integral view.. Cancer biology & therapy(IF=4.6). 2011. PMID:22057267. DOI: 10.4161/cbt.12.11.18140.
  • [30] Diana Xochiquetzal Robledo-Cadena;Silvia Cecilia Pacheco-Velazquez;Jorge Luis Vargas-Navarro;Joaquín Alberto Padilla-Flores;Rafael Moreno-Sanchez;Sara Rodríguez-Enríquez. Mitochondrial Proteins as Metabolic Biomarkers and Sites for Therapeutic Intervention in Primary and Metastatic Cancers.. Mini reviews in medicinal chemistry(IF=3.3). 2024. PMID:39004839. DOI: 10.2174/0113895575254320231030051124.
  • [31] Fabio Ferro;Stéphane Servais;Pierre Besson;Sébastien Roger;Jean-François Dumas;Lucie Brisson. Autophagy and mitophagy in cancer metabolic remodelling.. Seminars in cell & developmental biology(IF=6.0). 2020. PMID:31154012. DOI: 10.1016/j.semcdb.2019.05.029.
  • [32] Nan Niu;Jinfeng Ye;Zhangli Hu;Junbin Zhang;Yun Wang. Regulative Roles of Metabolic Plasticity Caused by Mitochondrial Oxidative Phosphorylation and Glycolysis on the Initiation and Progression of Tumorigenesis.. International journal of molecular sciences(IF=4.9). 2023. PMID:37108242. DOI: 10.3390/ijms24087076.
  • [33] Jacopo Di Gregorio;Sabrina Petricca;Roberto Iorio;Elena Toniato;Vincenzo Flati. Mitochondrial and metabolic alterations in cancer cells.. European journal of cell biology(IF=4.3). 2022. PMID:35453093. DOI: 10.1016/j.ejcb.2022.151225.
  • [34] Lan Shen;Xiang Sun;Zhenhong Fu;Guodong Yang;Jianying Li;Libo Yao. The fundamental role of the p53 pathway in tumor metabolism and its implication in tumor therapy.. Clinical cancer research : an official journal of the American Association for Cancer Research(IF=10.2). 2012. PMID:22307140. DOI: 10.1158/1078-0432.CCR-11-3040.
  • [35] Matthew D Hirschey;Ralph J DeBerardinis;Anna Mae E Diehl;Janice E Drew;Christian Frezza;Michelle F Green;Lee W Jones;Young H Ko;Anne Le;Michael A Lea;Jason W Locasale;Valter D Longo;Costas A Lyssiotis;Eoin McDonnell;Mahya Mehrmohamadi;Gregory Michelotti;Vinayak Muralidhar;Michael P Murphy;Peter L Pedersen;Brad Poore;Lizzia Raffaghello;Jeffrey C Rathmell;Sharanya Sivanand;Matthew G Vander Heiden;Kathryn E Wellen; . Dysregulated metabolism contributes to oncogenesis.. Seminars in cancer biology(IF=15.7). 2015. PMID:26454069. DOI: 10.1016/j.semcancer.2015.10.002.
  • [36] Duojiao Wu;Leying Zhuo;Xiangdong Wang. Metabolic reprogramming of carcinoma-associated fibroblasts and its impact on metabolic heterogeneity of tumors.. Seminars in cell & developmental biology(IF=6.0). 2017. PMID:27833036. DOI: 10.1016/j.semcdb.2016.11.003.
  • [37] Chitra Thakur;Fei Chen. Connections between metabolism and epigenetics in cancers.. Seminars in cancer biology(IF=15.7). 2019. PMID:31185282. DOI: 10.1016/j.semcancer.2019.06.006.
  • [38] Monica Neagu;Carolina Constantin;Iulia Dana Popescu;Donato Zipeto;George Tzanakakis;Dragana Nikitovic;Concettina Fenga;Constantine A Stratakis;Demetrios A Spandidos;Aristidis M Tsatsakis. Inflammation and Metabolism in Cancer Cell-Mitochondria Key Player.. Frontiers in oncology(IF=3.3). 2019. PMID:31139559. DOI: 10.3389/fonc.2019.00348.
  • [39] Youwu Hu;Wanqing Liu;WanDi Fang;Yudi Dong;Hong Zhang;Qing Luo. Tumor energy metabolism: implications for therapeutic targets.. Molecular biomedicine(IF=10.1). 2024. PMID:39609317. DOI: 10.1186/s43556-024-00229-4.
  • [40] Karthik Vasan;Marie Werner;Navdeep S Chandel. Mitochondrial Metabolism as a Target for Cancer Therapy.. Cell metabolism(IF=30.9). 2020. PMID:32668195. DOI: 10.1016/j.cmet.2020.06.019.
  • [41] Lan Huang;Cindy Wang;Huaxi Xu;Guangyong Peng. Targeting citrate as a novel therapeutic strategy in cancer treatment.. Biochimica et biophysica acta. Reviews on cancer(IF=8.3). 2020. PMID:31751601. DOI: 10.1016/j.bbcan.2019.188332.
  • [42] Rundong Liu;Chendong Wang;Zhen Tao;Guangyuan Hu. Lipid Metabolism Reprogramming in Cancer: Insights into Tumor Cells and Immune Cells Within the Tumor Microenvironment.. Biomedicines(IF=3.9). 2025. PMID:40868150. DOI: 10.3390/biomedicines13081895.
  • [43] Sakshi Pajai;Jyoti E John;Satyendra Chandra Tripathi. Targeting immune-onco-metabolism for precision cancer therapy.. Frontiers in oncology(IF=3.3). 2023. PMID:36816957. DOI: 10.3389/fonc.2023.1124715.
  • [44] Jingsong Ma;Mengya Zhong;Yubo Xiong;Zhi Gao;Zhengxin Wu;Yu Liu;Xuehui Hong. Emerging roles of nucleotide metabolism in cancer development: progress and prospect.. Aging(IF=3.9). 2021. PMID:33952722. DOI: 10.18632/aging.202962.
  • [45] Ibrahim H Ibrahim;Cheng-Han Lin;Ming Zhou;Jer-Yen Yang;Robert W Sobol;Ming Tan. Exploiting metabolic vulnerabilities to improve cancer therapeutics.. Trends in endocrinology and metabolism: TEM(IF=12.6). 2025. PMID:40883193. DOI: 10.1016/j.tem.2025.08.002.
  • [46] Xiaozhuang Zhou;Shruthi Kandalai;Farzana Hossain;Qingfei Zheng. Tumor microbiome metabolism: A game changer in cancer development and therapy.. Frontiers in oncology(IF=3.3). 2022. PMID:35936744. DOI: 10.3389/fonc.2022.933407.
  • [47] Alba Luengo;Dan Y Gui;Matthew G Vander Heiden. Targeting Metabolism for Cancer Therapy.. Cell chemical biology(IF=7.2). 2017. PMID:28938091. DOI: 10.1016/j.chembiol.2017.08.028.

MaltSci Intelligent Research Services ​

Search for more papers on MaltSci.com ​

cancer metabolism · tumor growth · Warburg effect · tumor microenvironment · metabolic reprogramming

© 2025 MaltSci